Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of Sodium Oligomannate Capsules in Alzheimer's disease
ChiCTR2000039219Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2020
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sodium oligomannate in Alzheimer's disease (AD) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Adverse reactions and Therapeutic effect (cognitive function improvement). Started Nov 2020; status: recruiting.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2000039219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039219.